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Introduction
Despite the recent advances in percutaneous inter ven-
tion, drug and device therapy, patients with acute myo-
cardial infarction (AMI) and resulting left ventricular 
impairment have 13% mortality at 1  year [1]. Following 
the loss of over one billion cardiomyocytes in a func-
tionally signiﬁ cant MI, the overloaded surviving cardio-
myocytes undergo abnormal remodelling, eventually 
leading to heart failure. Th is condition, a leading cause of 
death and disability in the developed world, is associated 
with 5-year mortality rates of up to 70% in symptomatic 
patients [2]. Current conventional therapies do not correct 
underlying defects in cardiac muscle cell number [3].
Th e only therapeutic option that currently addresses 
cardiomyocyte loss is heart transplantation. However, 
due to stringent selection criteria and chronic shortage of 
donor hearts, the vast majority of patients are deemed 
unsuitable or never receive a transplant. Th erefore, 
preventing this progression post-MI is a major challenge 
requiring novel therapeutic strategies such as stem cell 
transplantation to improve the prognosis and quality of 
life for these patients.
Th e traditional view that the heart is a terminally 
diﬀ erentiated organ has been challenged by the discovery 
of diﬀ erentiation of stem cells into cardiomyocytes in 
animal and human hearts [4-7]. Th is in turn has led to 
the exciting possibility for regenerative therapy for 
cardio myocyte loss after a MI. Th e demonstration of 
functional recovery of myocardium through cardiomyo-
genesis and neoangiogenesis in AMI in murine models 
by Orlic and colleagues [8] generated tremendous interest 
in the potential of bone marrow-derived stem cells. Since 
then, the cardiomyogenic ability of these cells has been 
challenged. However, studies continue to demon strate 
improvement in cardiac function and reduction in infarct 
size. It should be noted that progenitor cells also 
contribute to cardiac repair by mechanisms beyond the 
growth of new cardiomyocytes and as such may oﬀ er an 
‘indirect’ beneﬁ t.
Animal and human trials
Th e most promising and obvious cell type for the growth 
of new cardiomyocytes is the embryonic stem cell; 
however, considerable technical and ethical issues exist 
with these cells, which must be overcome before their 
successful use in humans. Adult stem cells are an 
attractive option to explore for transplantation as they 
are autologous, but their diﬀ erentiation potential is more 
restricted than embryonic stem cells. Currently, the 
major sources of adult cells used for basic research and in 
clinical trials originate from the bone marrow. Th e bone 
marrow mononuclear subset is heterogeneous and com-
prises mesenchymal stem cells, haematopoietic progenitor 
cells and endothelial progenitor cells. Th e diﬀ erentiation 
capacity of diﬀ erent populations of bone marrow-derived 
stem cells into cardiomyocytes has been studied 
intensively. Th e results are rather confusing and diﬃ  cult 
to compare, since diﬀ erent isolation and identiﬁ cation 
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methods have been used to determine the cell population 
studied. To date, only mesenchymal stem cells seem to 
form cardiomyocytes, and only a small percentage of this 
population will do so in vitro or in vivo. Pragmatically, 
the translation of the basic science into clinical research 
has followed a common pathway: injection of bone 
marrow-derived mononuclear cells (BMMNCs) as a 
source of stem cells into the heart. Table 1 provides a 
summary of clinical trials using BMMNCs in patients 
with acute MI.
Trials with no sham bone marrow harvest or intracoronary 
re-infusion in the control group
In the ﬁ rst human trial, Strauer and colleagues [9] re-
infused intracoronary BMMNCs 7 days after myocardial 
infarction (MI). Th e mean number of mononuclear cells 
was 2.8  ×  107. Th ere was a signiﬁ cant improvement in 
myocardial perfusion and a reduction in the infarct 
region in the cell therapy group. Th e Transplantation of 
Progenitor Cells and Regeneration Enhancement in 
Acute Myocardial Infarction (TOPCARE-AMI) investi-
gators randomised patients into intracoronary infusion of 
BMMNCs or ex vivo expanded circulating progenitor 
cells 4  days after MI [10]. Th ere was a signiﬁ cant 
improve ment in global and regional left ventricular (LV) 
function in both groups and a beneﬁ cial eﬀ ect on the 
post-infarction remodelling process manifest by a 
profound improvement in wall motion abnormalities in 
the infarct area and a signiﬁ cant reduction in end-systolic 
LV volume at 4 months post-MI. Th e LV ejection fraction 
(LVEF) further improved at 12  months, resulting in a 
total increase of 9.3% at 1 year [11]. Of interest, there was 
no diﬀ erence between the two active treatment groups. 
Th e mean number of infused cells was 245 × 106, which 
contained haematopoietic progenitor, mesenchymal and 
stromal cells. However, a major limitation of both of 
these trials was the lack of a control group receiving sham 
bone marrow harvest or intracoronary re-infusion.
Another trial in which there was no sham procedure is 
the Autologous Stem-Cell Transplantation in Acute 
Myocardial Infarction (ASTAMI) trial, which included 
only patients with acute anterior MI. Th e intracoronary 
re-infusion of BMMNCs 4 to 8 days after infarction did 
not have a beneﬁ cial eﬀ ect on LVEF compared to percu-
taneous coronary intervention (PCI) alone at 6  months 
[12]. Th is lack of beneﬁ cial eﬀ ect may be explained by the 
diﬀ erent cell processing protocols used in this trial. Cell 
processing protocols may have a signiﬁ cant impact on 
the functional capacity of bone marrow-derived stem 
cells [13]. Comparison of diﬀ erent isolation protocols 
revealed a vastly reduced recovery of mononuclear cells 
and nulliﬁ cation of the neovascularisation capacity when 
the ASTAMI cell isolation and storage protocol was used 
[13].
Th e Bone Marrow Transfer to Enhance ST-Elevation 
Infarct Regeneration (BOOST) trial, a slightly larger trial, 
included 60 patients that were randomised to receive 
intra coronary BMMNCs or standard therapy 4.8  days 
after successful PCI following AMI. Th ere was a signi-
ﬁ cant improvement in global LVEF in the cell treatment 
group at 6 months without an eﬀ ect on LV remodelling 
[14]. However, this improvement was not maintained at 
18 months. Th e mean number of bone marrow cells that 
were infused contained 9.5  ×  106 CD34+ and 3.6  ×  106 
haematopoietic colony-forming cells. Th e improvement 
in LVEF did not correlate with the number of CD34+ cells 
or haematopoietic colony forming cells. Again, a major 
limitation of the BOOST trial is that the control group 
did not undergo a sham bone marrow harvest or 
intracoronary infusion.
Th e ﬁ rst long-term study involving 62 patients who 
underwent intracoronary BMMNC transplantation 
7 days post-AMI not only resulted in an early signiﬁ cant 
improvement in ejection fraction (EF) and infarct size, 
but there was also a signiﬁ cant reduction in mortality 
and improvement in exercise capacity compared to 
controls at 5 years [15].
Randomised controlled trials
Th e Transcatheter Transplantation of Stem Cells for 
Treat ment of Acute Myocardial Infarction (TCT-STAMI) 
trial, which included a control group receiving a placebo 
infusion, showed a signiﬁ cant (approximately 5%) improve-
ment in LVEF of patients receiving intracoronary 
BMMNCs at 6 months [16].
Intracoronary bone marrow derived progenitor cells 
in acute infarction (REPAIR-AMI), a large random ized 
double-blind controlled trial that included over 200 
patients, showed an improvement in the primary 
endpoint in the treatment group that was an absolute 
change in global LVEF from baseline to 4  months, as 
measured by quantitative left ventricular angiography 
[17]. Furthermore, the pre-speciﬁ ed cumulative end-
point of death, MI, or revascularisation was signiﬁ cantly 
reduced, and this beneﬁ t was maintained at one year 
follow-up [18]. Th e mean increase in LVEF in the 
BMMNC group was 2.5% and there was an inverse 
relationship between the baseline EF and the degree of 
improvement. For example, patients with a baseline EF 
below the median value (48.9%) had an absolute 
increase in global EF that was three times higher than 
that in the placebo group. In contrast, the improvement 
in LVEF in patients with a baseline EF that was above 
the median value was non-signiﬁ cant (0.3%). Th e timing 
of cell infusion post-PCI also had an eﬀ ect on the 
primary endpoint. Patients in whom the cells were 
infused ≥5  days post-PCI were the only ones who 
derived beneﬁ t.
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By contrast, the LEUVEN-AMI study by Janssens and 
colleagues [19] showed that intracoronary re-infusion of 
BMMNCs within 24  hours of reperfusion was asso-
ciated with a greater reduction in infarct size and 
improved regional systolic function, but no overall 
improve ment in global left ventricular function com-
pared to controls.
Trials that used two diff erent cell populations
More recently, the Myocardial Regeneration by Intra-
coronary Infusion of Selected Population of Stem Cells in 
Acute Myocardial Infarction (REGENT) trial, which 
included patients with anterior MI, uniquely compared 
two cell types. Patients were random ized to receive 
intracoronary infusion of unselected (n = 80) or selected 
CD34+CXCR4+ (n  =  80) BMMNCs, or to the control 
group (n = 40) [20]. Although patients in the treatment 
group had a 3% improvement in LVEF, this did not reach 
statistical signiﬁ cance. However, the primary endpoint 
analysis included <60% of the total population of patients, 
which is likely to be responsible for the failure in the 
improvement in LVEF to achieve statistical signiﬁ cance. 
Subgroup analysis showed that baseline EF below the 
median value (37%) was an indepen dent predictor of 
signiﬁ cant (≥5%) increase in LVEF after treatment with 
BMMNCs.
Table 1. Clinical trials using autologous bone marrow mononuclear cells in patients with acute myocardial infarction
 Study Cell Delivery Timing Adjunct 
Study  design type method post-infarction procedure Outcome
Meluzin et al. [93] RCT BMMNC IC 5-9 days PCI Dose-dependent improvement of regional myocardial 
      function by PET
Fernandez-Aviles et al. [94] NR BMMNC IC 13.5 ± 5.5 days PCI Decrease in end systolic volume, improvement in regional 
      and global function
Janssens et al. [19] RCT BMMNC IC 1 day PCI No eff ect on global LVEF, but may favourably aff ect infarct 
      remodelling
Lunde et al. [12] (ASTAMI) RCT BMMNC IC 6 days PCI No eff ect on global LVEF
Schächinger et al. [17]  RCT BMMNC  IC 3-7 days PCI Improvement in global LVEF
(REPAIR-AMI)
Ge et al. [16] RCT BMMNC IC Immediately  PCI Improvement in LVEF
De Lezo et al. [95] RCT BMMNC IC 7 days IV  Improvement in LVEF
  or GCSF   fi brinolytics 
     + PCI
Zhan-quan et al. [96] NRC PBSC IC 6 days PCI Improvement in LVEF
Wollert et al. [14] (BOOST) RCT BMMNC IC 4.8 days PCI Improvement in LV systolic function
Lipiec et al. [97] RCT BMMNC IC 4-11 days PCI Improvement in myocardial perfusion with no eff ect on 
      global LVEF
Huikuri et al. [98]  RCT BMMNC IC 2-6 days IV  Improvement in global LVEF
(FINCELL)     thrombolysis 
     + PCI
Kang et al. [99] RCT PBSC IC  PCI Improvement in myocardial perfusion and systolic 
  and GCSF    function
Assmus et al. [10]  NR BMMNC IC 3-7 days PCI Improvement in LVEF
(TOPCARE-AMI)  or CPC
Schächinger et al. [11]  NR BMMNC IC 3-7 days PCI Improvement in EF
(TOPCARE-AMI)  or CPC
Strauer et al. [9] NRC BMMNC IC 5-9 days PCI Reduction in infarct region
Bartunek et al. [100]  NRC BMMNC (CD133) IC 11.6 days PCI Improvement in LVEF
Hirsch et al. [21] RCT BMMNC IC 3-8 days PCI No eff ect on global or regional LV function
Tendera et al. [20] RCT BMMNC IC 3-12 days PCI No signifi cant improvement in LVEF
Chen et al. [101] RCT BMMNC IC 18 days PCI Improvement in LVEF
Yousef et al. [15] (BALANCE) NRC BMMNC IC 7 days PCI Improvement in LVEF, exercise capacity and mortality
Time from myocardial infarction to transplantation and outcomes measured are listed. ASTAMI, Autologous Stem-Cell Transplantation in Acute Myocardial Infarction; 
BMMNC, bone marrow-derived mononuclear cell; BOOST, Bone Marrow Transfer to Enhance ST-Elevation Infarct Regeneration; CPC, circulating progenitor cell; EF, 
ejection fraction; GCSF, granulocyte-colony stimulating factor; IC, intracoronary; IM, intramyocardial; LVEF, left ventricular ejection fraction; NR, non-randomised; NRC, 
non-randomised with control group; PBSC, peripheral blood stem cell; PCI, percutaneous coronary intervention; PET, positron emission tomography; RCT, randomised 
controlled trial; REPAIR-AMI, Reinfusion of Enriched Progenitor Cells and Infarct Remodeling in Acute Myocardial Infarction; TOPCARE-AMI, Transplantation of 
Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction.
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Th e HEBE trial compared the intracoronary infusion of 
BMMNCs or mononuclear peripheral blood cells to 
standard therapy alone following an AMI [21]. Th e intra-
coronary BMMNCs were delivered between 3 to 8 days 
after AMI. Th ey showed no eﬀ ect of either treatment on 
regional or global left ventricular function.
Benefi ts beyond ejection fraction
A recent comprehensive systematic review that included 
13 trials with a total of 811 patients showed an 
improvement in LVEF by 2.99% in the BMMNC group 
compared to standard reperfusion therapy [22].
A previous meta-analysis by Lipinski and colleagues 
[23] that included 10 trials with AMI showed that intra-
coronary stem cell therapy (within the ﬁ rst 14 days after 
infarction) was associated with a small but signiﬁ cant 
(3.0%) improvement in LV systolic function compared 
to standard medical therapy. It was also associated with 
a non-signiﬁ cant reduction in death and re-
hospitalisation from heart failure. Although they found 
no signiﬁ cant association between the beneﬁ ts of 
intracoronary cell injection and the number of injected 
cells, there was a trend toward a statistically signiﬁ cant 
association with the injected volume, suggesting the 
possible presence of a dose-response relationship. Th e 
improvement in LVEF was observed in both bone 
marrow and peripheral mononuclear cells. Similar 
conclusions were reached in the meta-analysis by 
Abdel-Latif and colleagues [24], which included 18 
studies and showed that stem cell therapy signiﬁ cantly 
increased LVEF by 3.66%.
In contrast to animal models, the improvement in LV 
function in most clinical trials is at best modest. 
However, it should be noted that several of our 
established therapies that have an impact on prognosis 
in patients with MI and a reduced LV function, such as 
angiotensin-converting enzyme inhibitors, β-blockers 
[25], thrombolytic therapy and percutaneous coronary 
intervention [26,27], are associated with similar 
improve ments in LVEF. It is likely that adult stem cells 
exert their beneﬁ t on cardiac remodelling through an 
‘indirect’ para crine eﬀ ect, and that the small functional 
beneﬁ t seen with this therapy may translate into signiﬁ -
cant long-term improvement in exercise tolerance and 
survival [15].
Th e main surrogate markers used as an end-point have 
been EF and perfusion defects, which correlate poorly 
with prognosis and quality of life [28,29]. Th erefore, in 
the future, the validation of progenitor cell therapy for 
clinical use may depend on the demonstration of a 
beneﬁ t with regard to clinical outcomes such as improve-
ment in prognosis, quality of life [30], New York Heart 
Association functional classiﬁ cation and exercise 
capacity.
The debated hypothesis
Th e divergent ﬁ ndings from current trials may be due to 
several factors. Th ere appears to be an inverse relation-
ship between the beneﬁ t seen with stem/progenitor cell 
therapy and the baseline LV function, with cell therapy 
being most eﬀ ective in patients with a lower LVEF 
[17,20]. Furthermore, patients with longer ischaemic 
time (>5  hours) may be more likely to have signiﬁ cant 
improve ment of LVEF following the BMMNC infusion 
[20].
Th e timing of cell infusion may also play a role on the 
derived beneﬁ t. Although the REPAIR-AMI trial suggests 
that the enhanced improvement of the LVEF was con-
ﬁ ned to patients who were treated ≥5 days after primary 
PCI, the investigators of the HEBE and REGENT trials 
showed no interaction between the timing of cell infusion 
and derived beneﬁ t. Th e meta-analysis by Martin-
Rendon and colleagues [22], however, showed that the 
beneﬁ t of stem cell therapy was even greater when the 
BMMNCs were infused >7  days after MI. Th e eﬀ ect of 
timing on the beneﬁ cial eﬀ ects of BMMNC adminis tra-
tion is further supported by the study by Lai and 
colleagues [31] that showed that intracoronary BMMNC 
administration provided cardio-protection in a fashion 
similar to ishaemic preconditioning. Th is beneﬁ t was 
only seen when the myocardium had not been pre-
conditioned by other means. An ongoing study at our 
centre, the REGENERATE-AMI (ClinicalTrial.gov 
NCT00765453), is designed to study the delivery of 
BMMNCs at very early time points (within 6  hours of 
PCI). Th e purpose of this design is to replicate the animal 
models where very early interventions lead to a signiﬁ -
cant (40%) improvement in cardiac function [8].
Th e dose of infused BMMNCs has varied between 
diﬀ erent trials with variable results. Th ere appears to be a 
dose-dependent improvement in EF, with the beneﬁ t of 
BMMNCs only seen when doses higher than 108 are 
administered [22].
Direct (transdiff erentiation) and indirect (paracrine 
and angiogenesis) eff ects of stem cells
To date, there is no direct clinical evidence that cellular 
cardiomyogenesis in fact occurs in the human heart after 
transplantation of progenitor cells, and over the past few 
years, various experiments using diﬀ erent types of stem 
cells have shown that <2% of the transplanted cells trans-
diﬀ erentiate into cardiomyocytes [32]. Th erefore, the 
number of cardiac cells produced by cardiac re genera tion 
alone is unlikely to explain the eﬀ ects seen. In experi ments 
using a mouse model of MI, bone marrow-derived cells 
were shown to undergo a very low level of trans-
diﬀ erentiation into cardiomyocytes and most of these cells 
continued to diﬀ erentiate along the haematopoietic lineage 
[33,34]. However, engraftment of these haemato poietic 
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cells at the infarct site led to an improvement in 
myocardial function that is likely attributed to vasculo-
genesis, angiogenesis and a paracrine eﬀ ect. Adult stem 
cells secrete a variety of cytokines, chemokines, and 
growth factors that are involved in cardiac repair [35] and 
the production of these factors is increased in response 
to the hypoxic stress associated with AMI [36]. Takahashi 
and colleagues [37] showed that BMMNCs in rats pro-
duce and release various cytoprotective factors, including 
vascular endothelial growth factor, platelet-derived 
growth factor, interleukin-1β, and insulin-like growth 
factor-1, some of which are signiﬁ cantly up-regulated by 
hypoxia. Th ese paracrine factors may inﬂ uence adjacent 
cells and exert their actions via several mechanisms, 
including myocardial protection and neovascularisation. 
Furthermore, in humans, direct injection of BMMNCs 
during acute ischaemia results in a direct cardioprotective 
eﬀ ect, by abolishing the process of apoptosis and necrosis 
[38], which in part explains the clinical beneﬁ t seen in 
clinical trials. Th is cardioprotective mechanism appears 
to be dose related with the beneﬁ t only seen with injected 
doses that are ≥5 × 106.
Neo-angiogenesis in the peri-infarct zone is an integral 
part of the cardiac remodelling process [39]. Under 
normal circumstances, however, this is seldom suﬃ  cient 
to meet the demands of the hypertrophied myocardium, 
and the compensatory tissue growth required for myo-
cardial contractility. One of the therapeutic advantages of 
bone marrow-derived cells is to induce therapeutic 
angiogenesis in ischaemic tissues, which in turn would 
augment oxygen supply [40-43], and help rescue cells 
from critical ischaemia [44]. Dowell and colleagues [45] 
have shown with histological examination at 2 weeks post-
infarction that injection of CD34+ cells was accompanied 
by a signiﬁ cant increase in infarct zone microvascularity, 
cellularity and ﬁ brosis in comparison to controls. Th ey 
also showed that neoangiogenesis was increased within 
both the infarct zone and the peri-infarct rim in rats 
receiving CD34+ cells compared with saline controls [45].
Paracrine factors released by transplanted stem cells 
may alter the extracellular matrix, resulting in more 
favourable post-infarction remodelling and strengthening 
of the infarct scar. In animal models of MI, the injection 
of endothelial progenitor cells or bone marrow-derived 
stem cells signiﬁ cantly improved blood ﬂ ow and cardiac 
function and reduced left ventricular scarring [46,47]. 
After an ischaemic event, the eﬃ  ciency of engrafment 
diﬀ ers between diﬀ erent progenitor subpopulations 
[48,49]. Th e formation of new blood vessels occurs as a 
result of the interaction of diﬀ erent types of stem cells 
with cardiomyocytes [46,50-53]. Neovascularisation is 
mediated by the physical integration of progenitor cells 
into new capillaries [48,54], or through a paracrine eﬀ ect 
by releasing growth factors that promote angiogenesis 
[55], depending on the cell type and the circumstances of 
the cardiac injury.
Route of cell administration
Th e three routes of stem cell delivery that have been used 
so far in clinical trials are through intracoronary or 
intramyocardial injection or peripherally through the 
systemic circulation. It is not yet possible on the basis of 
existing clinical studies to assert a ‘best’ mode of delivery. 
However, it is likely that patients’ individual pathobiology 
as well as the aetiology of their cardiac dysfunction will 
ultimately dictate the route chosen among potential 
progenitor cell therapies. Th e advantage of intracoronary 
delivery is that cells are directly injected into areas of 
good blood supply rich in nutrients and oxygen, which is 
essential for cell survival. Myocardial ischemia is a major 
stimulus for incorporation of circulating progenitor cells, 
and potently up-regulates the chemo-attractants for 
neoangiogenesis. Even after infarction, however, the 
absolute number of progenitor cells detected in the heart 
is very low [40,41,56,57], but intracoronary infusion of 
progenitor cells may enhance local accumulation and 
homing compared to intravenous injection.
By contrast, the beneﬁ t of direct intramyocardial cell 
delivery into hibernating myocardium is that it negates 
the need for the uptake of progenitor cells from the 
circulation. Electromechanical (NOGA) mapping is 
essential to ensure that the cells are injected in areas of 
hibernating myocardium [58], as necrotic areas of 
myocardium and scar tissue lack the necessary cues for 
cells to engraft and diﬀ erentiate, and cells injected in 
these areas die immediately [59].
Homing
While homing of haematopoietic progenitor cells to bone 
marrow has been widely studied [60], the mechanisms of 
homing of progenitor cells to areas of tissue injury remain 
poorly understood. Homing is a complex process involving 
integrins and chemokine receptors, which is greatly 
enhanced after myocardial ischaemia and hypoxia. It 
includes adhesion to and transmigration through the 
endothelium followed by migration and invasion of the 
target tissue. Homing of cells is dependent on migration out 
of the vessel into the surrounding myocardium; therefore, 
underperfused regions of the myocardium are targeted in a 
less eﬃ  cient manner [61]. Th e two key factors that play an 
important role in homing after a MI are the release of 
stromal-cell-derived factor (SDF)-1 and a chromatin 
binding protein (HMGB1). SDF-1 regulates homing of stem 
cells to ischaemic tissue through integrin-dependent 
adhesion [62-64], and local delivery of SDF-1 can enhance 
progenitor cell recruitment and neovasculari sation [65,66]. 
Th e release of HMGB1 may act as a danger signal and 
stimulate the homing of stem cells to ischaemic tissue [67].
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Furthermore, endothelial progenitor cells express a 
number of chemokine receptors, such as CXCR2, CXCR4 
and CXCL12. Th ese chemokines play an important role 
in the homing and mobilisation of endothelial progenitor 
cells and their recruitment to the site of ischaemic injury 
for endothelial recovery [68-71].
Where is research in this area heading in the next 
few years?
Th e need for new therapies to treat patients with AMI 
has led to a swift transition from bench to bedside and a 
number of clinical trials showing promising potential for 
stem cell therapy in heart disease. Th e ultimate aim of 
this research is to develop a technique that grows new 
functioning heart muscle. However, many obstacles still 
lie ahead. One of the many remaining unanswered 
questions is which type of stem/progenitor cell is the best 
candidate for cardiac regeneration. Th e bone marrow is 
an attractive source because it is easily accessible and 
contains a number of stem cells, including haemato-
poietic and mesenchymal cells. It is likely, however, that 
bone marrow cells in humans work through an indirect 
paracrine mechanism. Th e safety and feasibility of bone 
marrow cells in AMI have been well established in 
clinical trials. Th is, therefore, supports the need for 
robust evidence from large double-blind randomised 
controlled trials to assess their eﬀ ect on clinical end-
points such as mortality and symptoms.
Th e European Society of Cardiology established a task 
force to investigate the role of stem cells in cardiac repair 
and published its consensus in a 2006 report [72]. Th e 
future focus in stem cell therapy should be to provide a 
better understanding of the mechanism of functional 
improvements observed and the development of safe and 
eﬀ ective cell tracking modalities. Th ese areas of research 
would aid the identiﬁ cation of the best cell candidate for 
therapeutic use as well as better understanding of myo-
cardial homing and cell survival post-transplantation. It 
is important to note, however, that the clinical experience 
has provided a lot of valuable information regarding the 
approaches to cell therapy in humans, which will of 
course provide a platform for future trials in this ﬁ eld.
One of the challenges in the future is improving the 
durability and survival of stem cells in the adverse 
environ ment they are engrafted into. One of the proper-
ties of stem cells is stress resistance [73], although several 
studies have shown that most stem cells die within a few 
weeks of delivery into the myocardium [34,74-76]. Th is is 
probably due to the lack of nutrients and oxygen within 
the ischaemic environment. Furthermore, heart failure 
[77], atherosclerosis [78,79] and advanced age [80,81] 
correlate inversely with the number and function of 
circulating endothelial progenitor cells. Allogenic cells 
from young and healthy donors may represent a good 
solution, but cell rejection requiring immunosuppressive 
therapies would pose a new problem. Th ere is some evi-
dence that statins improve the survival of the circulating 
endothelial progenitor cells [82,83]. Furthermore, higher 
doses of statin therapy are associated with a greater 
increase in circulating CD34+ and CXCR4+ from the bone 
marrow, resulting in an increase in coronary ﬂ ow reserve 
at 8 months [84]. Future trials are on the horizon assess-
ing the role of statin therapy on enhancing the number of 
endothelial cells in patients with coronary artery disease 
(Clinicaltrials.gov CT01096875). Endothelial progenitor 
cells are a subset of haematopoietic cells that have an 
important role to play in ischaemia by promoting angio-
genesis, preventing cardiomyocyte apoptosis and reduc-
ing adverse remodelling. It may be that future potential 
remedies, such as statins, that enhance the function of 
endothelial progenitor cells may play an important role in 
improving stem cell survival and function. One of the 
ways of improving cell survival may be achieved by using 
viral vectors encoding multiple cytoprotective genes that 
act on diﬀ erent cell death and apoptotic pathways, or by 
preconditioning the stem cells with cytokines that result 
in improved cell engraftment.
Another important issue is the timing of cell adminis-
tration post-MI. Although animal studies have supported 
early administration of stem cells post-infarction, in 
humans the beneﬁ ts of this therapy were greater when 
administered >4 days after reperfusion (based on avail able 
evidence). Furthermore, given the seemingly small 
improvements that these trials have shown, the cost-
eﬀ ective ness of cell therapy will also need to be addressed.
Two ongoing randomised controlled trials (TIME and 
late TIME studies) may help us understand whether the 
timing of cell administration plays an important role. Th e 
TIME study (Clinicaltrials.gov NCT00684021) is a trial 
designed to assess the eﬀ ect of timing (3 versus 7 days) of 
BMMNC administration versus placebo in patients with 
acute MI. Th e LATE TIME study (Clinicaltrials.gov 
NCT00684060) will assess the eﬀ ect of BMMNC adminis-
tra tion 2 to 3 weeks after a MI.
Future cells
Animal and human studies have clearly shown that stem 
cell engraftment into the myocardium is associated with 
improvement in cardiac function; however, the quest for 
the optimal population of cells remains a challenge 
[85,86]. Embryonic stem cells are able to transform into 
cardiomyocytes and can replicate indeﬁ nitely, although 
ethical issues - their potential to form teratomas and the 
need for immunosuppressive therapy  - have hindered 
their use in clinical trials. Furthermore, one of the major 
limitations of adult stem cells, including skeletal 
myoblasts and bone marrow-derived stem cells, is their 
limited ability to cross their lineage boundaries.
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Fat tissue-derived multipotent stem cells [87], multi-
potential cells from bone marrow or skeletal muscle 
[88,89], somatic stem cells from placental cord blood [90], 
and cardiac-resident progenitor cells [32,91] all show 
promising pre-clinical and some clinical applications.
Ultimately, cells that more closely resemble embryonic 
stem cells in their regenerative potential without the 
ethical issues provide an important future direction. A 
cell type that comes close, and is on the horizon of being 
tested for potential clinical application, is the inducible 
pluripotent stem cell (iPSC). iPSCs can be generated 
from adult human somatic cells by retroviral transduction 
[92], have similar diﬀ erentiation potential and may 
provide an alternative to pluripotent embryonic stem 
cells.
The future of bone marrow stem cells
For the time being, it is important to establish whether 
the simple unfractionated bone marrow cell approach 
has clinical beneﬁ t, given the large number of studies that 
have been performed using this cell type without provid-
ing a clear answer. Meta-analysis suggests a positive 
eﬀ ect on surrogate cardiac end-points in studies using 
BMMNCs to treat AMI. Th ere is now a need to perform 
a large scale clinical trial using clinical hard end-points 
such as mortality to establish whether the positive eﬀ ects 
seen on surrogate end-points can indeed translate to 
meaningful clinical beneﬁ ts.
Abbreviations
AMI, acute myocardial infarction; ASTAMI, Autologous Stem-Cell 
Transplantation in Acute Myocardial Infarction; BMMNC, bone marrow-
derived mononuclear cell; BOOST, Bone Marrow Transfer to Enhance ST-
Elevation Infarct Regeneration; EF, ejection fraction; LV, left ventricular; LVEF, 
left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous 
coronary intervention; REPAIR-AMI, Intracoronary bone marrow derived 
progenitor cells in acute infarction; SDF, stromal-cell-derived factor.
Competing interests
The authors have no relevant affi  liations or fi nancial involvement with any 
organisation or entity with a fi nancial interest in or fi nancial confl ict with 
the subject matter or materials discussed in the manuscript. This includes 
employment, consultancies, honoraria, stock ownership or options, expert 
testimony, grants or patents received or pending, or royalties. No writing 
assistance was utilized in the production of this manuscript.
Acknowledgements
This work forms part of the research themes contributing to the translational 
research portfolio of Barts and the London Cardiovascular Biomedical 
Research Unit, which is supported and funded by the National Institute of 
Health Research.
Author details
1Department of Cardiology, London Chest Hospital, Bonner Road, London 
E2 9JX, UK. 2Department of Cardiology, London Chest Hospital, Queen Mary 
University of London, Barts and the London NHS Trust, Bonner Road, London 
E2 9JX, UK.
Published: 17 January 2012
References
1. Pfeff er M, John J, McMurray M, Velazquez E, Rouleau J: Valsartan, captopril, 
or both in myocardial infarction complicated by heart failure, left 
ventricular dysfunction, or both. N Eng J Med 2003, 349:1893-1906.
2. Braunwald E: Cardiovascular medicine at the turn of the millennium: 
triumphs, concerns, and opportunities. N Eng J Med 1997, 337:1360-1369.
3. Mathur A, Martin JF: Stem cells and repair of the heart. Lancet 2004, 
364:183-192.
4. Yeh TH, Zhang S, Wu H: Transdiff erentiation of human peripheral blood 
CD34+ enriched cell population into cardiomyocytes, endothelial cell and 
smooth muscle cells in vivo. Circulation 2003, 108:2070-2073.
5. Badorff  C: Transdiff erentiation of blood-derived human adult endothelial 
progenitor cells into functionally active cardiomyocytes. Circulation 2003, 
107:1024-1032.
6. Kawada H, Fujita J, Kinjo K: Non-haematopoietic mesenchymal stem cells 
can be mobilized and diff erentiate into cardiomyocytes after myocardial 
infarction. Blood 2004, 104:3581-3587.
7. Orlic D: Mobilized bone marrow cells repair the infarcted heart, improving 
function and survival. Proc Natl Acad Sci U S A 2001, 98:10344-10349.
8. Orlic D, Kajstrua J, Chimenti S: Bone marrow cells regenerate infracted 
myocardium. Nature 2001, 410:701-705.
9. Strauer B, Brehm M, Zeus T: Repair of infracted myocardium by autologous 
intracoronary mononuclear bone marrow cell transplantation in humans. 
Circulation 2002, 106:1913-1918.
10. Assmus B, Schächinger V, Teupe C: Transplantation of progenitor cells and 
regeneration enhancement in acute myocardial infarction 
(TOPCARE-AMI). Circulation 2002, 106:3009-3017.
11. Schächinger V, Assmus B, Britten M: Transplantation of progenitor cells and 
regeneration enhancement in acute myocardial infarction: Final one year 
results of the TOPCARE-AMI trial. J Am College Cardiol 2004, 44:1690-1699.
12. Lunde K, Solheim S, Aakhus S, Arnesen H, Abdelnoor M, Egeland T, Endresen 
K, Ilebekk A, Mangschau A, Fjeld JG, Smith HJ, Taraldsrud E, Grøgaard HK, 
Bjørnerheim R, Brekke M, Müller C, Hopp E, Ragnarsson A, Brinchmann JE, 
Forfang K: Intracoronary injection of mononuclear bone marrow cells in 
acute myocardial infarction. N Eng J Med 2006, 355:1199-1209.
13. Seeger FH, Tonn T, Krzossok N, Zeiher AM, Dimmeler S: Cell isolation 
procedures matter: a comparison of diff erent isolation protocols of bone 
marrow mononuclear cells used for cell therapy in patients with acute 
myocardial infarction. Eur Heart J 2007, 28:766-772.
14. Wollert K, Meyer G, Joachim L: Intracoronary autologous bone-marrow cell 
transfer after myocardial infarction: the BOOST randomised controlled 
clinical trial. Lancet 2004, 364:141-148.
15. Yousef M, Schannwell CM, Kostering M, Zeus T, Brehm M, Strauer BE: The 
BALANCE Study: clinical benefi t and long-term outcome after 
intracoronary autologous bone marrow cell transplantation in patients 
with acute myocardial infarction. J Am Coll Cardiol 2009, 53:2262-2269.
16. Ge J, Qian J: Effi  cacy of emergent transcatheter transplantation of stem 
cells for treatment of acute myocardial infarction (TCT-STAMI). Heart 2006, 
92:1764-1767.
17. Schächinger V, Erbs S, Elsässer A: REPAIR-AMI investigators. Intracoronary 
bone marrow derived progenitor cells in acute infarction. N Eng J Med 
2006, 355:1210-1221.
18. Schächinger V, Erbs S, Elsässer A, Haberbosch W, Hambrecht R, Hölschermann 
H, Yu J, Corti R, Mathey DG, Hamm CW, Süselbeck T, Werner N, Haase J, 
Neuzner J, Germing A, Mark B, Assmus B, Tonn T, Dimmeler S, Zeiher AM; 
REPAIR-AMI Investigators: Improved clinical outcome after intracoronary 
administration of bone-marrow-derived progenitor cells in acute 
myocardial infarction: fi nal 1-year results of the REPAIR-AMI trial. Eur Heart 
J 2006, 27:2775-2783.
19. Janssens S, Dubois C, Bogaert J: Autologous bone marrow derived stem cell 
transfer in patients with ST-segment elevation myocardial infarction: 
double blind randomised controlled trial. Lancet 2006, 367:113-121.
20. Tendera M, Wojakowski W, Ruzyłło W, Chojnowska L, Kepka C, Tracz W, 
Musiałek P, Piwowarska W, Nessler J, Buszman P, Grajek S, Breborowicz P, Majka 
M, Ratajczak MZ; REGENT Investigators: Intracoronary infusion of bone 
marrow-derived selected CD34+CXCR4+ cells and non-selected 
mononuclear cells in patients with acute STEMI and reduced left 
ventricular ejection fraction: results of randomized, multicentre 
Myocardial Regeneration by Intracoronary Infusion of Selected Population 
of Stem Cells in Acute Myocardial Infarction (REGENT) Trial. Eur Heart J 
2009, 30:1313-1321.
21. Hirsch A, Nijveldt R, van der Vleuten PA, Tijssen JG, van der Giessen WJ, Tio RA, 
Waltenberger J, ten Berg JM, Doevendans PA, Aengevaeren WR, Zwaginga JJ, 
Biemond BJ, van Rossum AC, Piek JJ, Zijlstra F; HEBE Investigators: 
Arnous et al. Stem Cell Research & Therapy 2012, 3:2 
http://stemcellres.com/content/3/1/2
Page 7 of 9
Intracoronary infusion of mononuclear cells from bone marrow or 
peripheral blood compared with standard therapy in patients after acute 
myocardial infarction treated by primary percutaneous coronary 
intervention: results of the randomized controlled HEBE trial. Eur Heart J 
2011, 32:1736-1747.
22. Martin-Rendon E, Brunskill SJ, Hyde CJ, Stanworth SJ, Mathur A, Watt SM: 
Autologous bone marrow stem cells to treat acute myocardial infarction: 
a systematic review. Eur Heart J 2008, 29:1807-1818.
23. Lipinski JM, Giuseppe GL, Zoccai B, Abbate A, Khianey R: Impact of 
intracoronary cell therapy on left ventricular function in the setting of 
acute myocardial infarction. J Am College Cardiol 2007, 50:1761-1767.
24. Abdel-Latif A, Bolli R, Tleyjeh IM, Montori VM, Perin EC, Hornung CA, Zuba-
Surma EK, Al-Mallah M, Dawn B: Adult bone marrow-derived cells for 
cardiac repair: a systematic review and meta-analysis. Arch Intern Med 2007, 
167:989-997.
25. Reff elmann T, Konemann S, Kloner RA: Promise of blood- and bone marrow-
derived stem cell transplantation for functional cardiac repair: putting it in 
perspective with existing therapy. J Am Coll Cardiol 2009, 53:305-308.
26. Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffi  n JJ, Guagliumi G, 
Stuckey T, Turco M, Carroll JD, Rutherford BD, Lansky AJ; Controlled 
Abciximab and Device Investigation to Lower Late Angioplasty 
Complications (CADILLAC) Investigators: Comparison of angioplasty with 
stenting, with or without abciximab, in acute myocardial infarction. N Engl 
J Med 2002, 346:957-966.
27. Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, 
Boulenc JM, Morice MC, Maillard L, Pansiéri M, Choussat R, Pinton P; ADMIRAL 
Investigators. Abciximab before Direct Angioplasty and Stenting in 
Myocardial Infarction Regarding Acute and Long-Term Follow-up: Platelet 
glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial 
infarction. N Engl J Med 2001, 344:1895-1903.
28. Curtis JP, Sokol SI, Wang Y, Rathore SS, Ko DT, Jadbabaie F, Portnay EL, 
Marshalko SJ, Radford MJ, Krumholz HM: The association of left ventricular 
ejection fraction, mortality, and cause of death in stable outpatients with 
heart failure. J Am Coll Cardiol 2003, 42:736-742.
29. Tribouilloy C, Rusinaru D, Mahjoub H, Soulière V, Lévy F, Peltier M, Slama M, 
Massy Z: Prognosis of heart failure with preserved ejection fraction: 
a 5 year prospective population-based study. Eur Heart J 2008, 29:339-347.
30. Sharif F, Bartunek J, Vanderheyden M: Adult stem cells in the treatment of 
acute myocardial infarction. Catheter Cardiovasc Interv 2011, 77:72-83.
31. Lai VK, Ang KL, Rathbone W, Harvey NJ, Galinanes M: Randomized controlled 
trial on the cardioprotective eff ect of bone marrow cells in patients 
undergoing coronary bypass graft surgery. Eur Heart J 2009, 30:2354-2359.
32. Oh H: Cardiac progenitor cells from adult myocardium: homing, 
diff erentiation, and fusion after infarction. Proc Natl Acad Sci U S A 2003, 
100:12313-12318.
33. Murry C, Soonpaa M, Reinecke H: Haematopoietic stem cells do not 
transdiff erentiate into cardiac myocytes in myocardial infarcts. Nature 
2004, 428:664-668.
34. Balsam L, Wagers A, Christensen J: Haematopoietic stem cells adopt mature 
haematopoietic fates in ischaemic myocardium. Nature 2004, 428:668-673.
35. Caplan AI, Dennis JE: Mesenchymal stem cells as trophic mediators. J Cell 
Biochem 2006, 98:1076-1084.
36. Kinnaird T, Stabile E, Burnett MS, Lee CW, Barr S, Fuchs S, Epstein SE: Marrow-
derived stromal cells express genes encoding a broad spectrum of 
arteriogenic cytokines and promote in vitro and in vivo arteriogenesis 
through paracrine mechanisms. Circ Res 2004, 94:678-685.
37. Takahashi M, Li TS, Suzuki R, Kobayashi T, Ito H, Ikeda Y, Matsuzaki M, Hamano 
K: Cytokines produced by bone marrow cells can contribute to functional 
improvement of the infarcted heart by protecting cardiomyocytes from 
ischemic injury. Am J Physiol Heart Circ Physiol 2006, 291:H886-H893.
38. Kubal C, Sheth K, Nadal-Ginard B, Galinanes M: Bone marrow cells have a 
potent anti-ischemic eff ect against myocardial cell death in humans. 
J Thorac Cardiovasc Surg 2006, 132:1112-1118.
39. Nelissen-Vrancken H, Debets J, Snoeckx L, Daemen M, Smits J: Time-related 
normalization of maximal coronary fl ow in isolated perfused hearts of rats 
with myocardial infarction. Circulation 1996, 93:349-355.
40. Takahashi T, Kalka C, Masuda H: Ischemia- and cytokine-induced 
mobilization of bone marrow-derived endothelial progenitor cells for 
neovascularization. Nat Med 1999, 5:434-438.
41. Kalka C, Masuda H, Takahashi T: Transplantation of ex vivo expanded 
endothelial progenitor cells for therapeutic neovascularization. Proc Natl 
Acad Sci U S A 2000, 97:3422-3427.
42. Folkman J: Therapeutic angiogenesis in ischemic limbs. Circulation 1998, 
97:1108-1110.
43. Asahara T: Isolation of putative progenitor cells for endothelial 
angiogenesis. Science 1997, 275:964-967.
44. Isner J, Asahara T: Angiogenesis and vasculogenesis as therapeutic 
strategies for postnatal neovascularization. J Clin Invest 1999, 
103:1231-1236.
45. Dowell JD, Rubart M, Pasumarthi KBS, Soonpaa MH, Field LJ: Myocyte and 
myogenic stem cell transplantation in the heart. Cardiovasc Res 2003, 
58:336-350.
46. Kocher A: Neovascularization of ischemic myocardium by human bone-
marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces 
remodeling and improves cardiac function. Nat Med 2001, 7:430-436.
47. Kawamoto A, Gwon HC, Iwaguro H, Yamaguchi JI, Uchida S, Masuda H, Silver 
M, Ma H, Kearney M, Isner JM, Asahara T: Therapeutic potential of ex vivo 
expanded endothelial progenitor cells for myocardial ischemia. Circulation 
2001, 103:634-637.
48. Urbich C, Heeschen C, Aicher A, Dembach E, Zeiher AM, Dimmeler S: 
Relevance of monocytic features for neovascularization capacity of 
circulating endothelial progenitor cells. Circulation 2003, 108:2511-2516.
49. Aicher A, Heeschen C, Mildner-Rihm C, Urbich C, Ihling C, Technau-Ihling K, 
Zeiher AM, Dimmeler S: Essential role of endothelial nitric oxide synthase 
for mobilization of stem and progenitor cells. Nat Med 2003, 9:1370-1376.
50. Fuchs S, Baff our R, Zhou Y: Transendocardial delivery of autologous bone 
marrow enhances collateral perfusion and regional function in pigs with 
chronic experimental myocardial ischaemia. J Am College Cardiol 2001, 
37:1726-1732.
51. Hamano K, Li T, Kobayashi T: Therapeutic angiogenesis induced by local 
autologous bone marrow cell implantation. Ann Thoracic Surg 2002, 
73:1210-1215.
52. Kamihata H, Matsubara H, Nishiue T: Improvement of collateral perfusion 
and regional function by implantation of peripheral blood mononuclear 
cells into ischemic hibernating myocardium. Arterioscler Thromb Vasc Biol 
2002, 22:1804-1810.
53. Kamihata H, Matsubara H, Nishiue T: Implantation of bone marrow 
mononuclear cells into ischemic myocardium enhances collateral 
perfusion and regional function via side supply of angioblasts, angiogenic 
ligands, and cytokines. Circulation 2001, 104:1046-1052.
54. Jackson K: Regeneration of ischemic cardiac muscle and vascular 
endothelium by adult stem cells. J Clin Invest 2001, 107:1395-1402.
55. Rehman J, Li J, Orschell CM, March KL: Peripheral blood “endothelial 
progenitor cells” are derived from monocyte/macrophages and secrete 
angiogenic growth factors. Circulation 2003, 107:1164-1169.
56. Shintani S, Murohara T, Ikeda H: Mobilization of endothelial progenitor cells 
in patients with acute myocardial infarction. Circulation 2001, 
103:2776-2779.
57. Iwaguro H, Yamaguchi J, Kalka C: Endothelial progenitor cell vascular 
endothelial growth factor gene transfer for vascular regeneration. 
Circulation 2002, 105:732-738.
58. Perin E: Transendocardial, autologous bone marrow cell transplantation 
for severe, chronic ischemic heart failure. Circulation 2003, 107:2294-2302.
59. Beauchamp J, Morgan J, Pagel C, Partridge T: Dynamics of myoblast 
transplantation reveal a discrete minority of precursors with stem cell-like 
properties as the myogenic source. J Cell Biol 1999, 144:1113-1122.
60. Papayannopoulou T: Bone marrow homing: the players, the playfi eld, and 
their evolving roles. Curr Opin Hematol 2003, 10:214-219.
61. Aicher A: Assessment of the tissue distribution of transplanted human 
endothelial progenitor cells by radioactive labeling. Circulation 2003, 
107:2134-2139.
62. De Falco E: Sdf-1 involvement in endothelial phenotype and ischemia-
induced recruitment of bone marrow progenitor cells. Blood 2004, 
104:3472-3482.
63. Chavakis E: Role of b2-integrins for homing and neovascularization 
capacity of endothelial progenitor cells. J Exp Med 2005, 201:63-72.
64. Vajkoczy P: Multistep nature of microvascular recruitment of ex vivo-
expanded embryonic endothelial progenitor cells during tumor 
angiogenesis. J Exp Med 2003, 197:1755-1765.
65. Askari A: Eff ect of stromal-cell-derived factor 1 on stem-cell homing and 
tissue regeneration in ischaemic cardiomyopathy. Lancet 2003, 
362:697-703.
Arnous et al. Stem Cell Research & Therapy 2012, 3:2 
http://stemcellres.com/content/3/1/2
Page 8 of 9
66. Yamaguchi J: Stromal cell-derived factor-1 eff ects on ex vivo expanded 
endothelial progenitor cell recruitment for ischemic neovascularization. 
Circulation 2003, 107:1322-1328.
67. Scaffi  di P, Misteli T, Bianchi M: Release of chromatin protein hmgb1 by 
necrotic cells triggers infl ammation. Nature 2002, 418:191-195.
68. Hristov M, Zernecke A, Bidzhekov K, Liehn EA, Shagdarsuren E, Ludwig A, 
Weber C: Importance of CXC chemokine receptor 2 in the homing of 
human peripheral blood endothelial progenitor cells to sites of arterial 
injury. Circ Res 2007, 100:590-597.
69. Levesque JP, Hendy J, Takamatsu Y, Simmons PJ, Bendall LJ: Disruption of the 
CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell 
mobilization induced by GCSF or cyclophosphamide. J Clin Invest 2003, 
111:187-196.
70. Petit I, Szyper-Kravitz M, Nagler A, Lahav M, Peled A, Habler L, Ponomaryov T, 
Taichman RS, Arenzana-Seisdedos F, Fujii N, Sandbank J, Zipori D, Lapidot T: 
G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 
and up-regulating CXCR4. Nat Immunol 2002, 3:687-694.
71. Yamaguchi J, Kusano KF, Masuo O, Kawamoto A, Silver M, Murasawa S, Bosch-
Marce M, Masuda H, Losordo DW, Isner JM, Asahara T: Stromal cell-derived 
factor-1 eff ects on ex vivo expanded endothelial progenitor cell 
recruitment for ischemic neovascularization. Circulation 2003, 
107:1322-1328.
72. Bartunek J, Dimmeler S, Drexler H, Fernández-Avilés F, Galinanes M, Janssens 
S, Martin J, Mathur A, Menasche P, Priori S, Strauer B, Tendera M, Wijns W, 
Zeiher A; task force of the European Society of Cardiology: The consensus of 
the task force of the European Society of Cardiology concerning the 
clinical investigation of the use of autologous adult stem cells for repair of 
the heart. Eur Heart J 2006, 27:1338-1340.
73. Ramalho-Santos M, Yoon S, Matsuzaki Y, Mulligan R, Melton D: “Stemness”: 
transcriptional profi ling of embryonic and adult stem cells. Science 2002, 
298:597-600.
74. Jiang S, Haider HK, Idris NM, Salim A, Ashraf M: Supportive interaction 
between cell survival signaling and angiocompetent factors enhances 
donor cell survival and promotes angiomyogenesis for cardiac repair. Circ 
Res 2006, 99:776-784.
75. Norol F, Bonnet N, Peinnequin A, Chretien F, Legrand R, Isnard R, Herodin F, 
Baillou C, Delache B, Negre D, Klatzmann D, Vernant JP, Lemoine FM: 
GFP-transduced CD34+ and Lin- CD34- hematopoietic stem cells did not 
adopt a cardiac phenotype in a nonhuman primate model of myocardial 
infarct. Exp Hematol 2007, 35:653-661.
76. Nakamura Y, Wang X, Xu C, Asakura A, Yoshiyama M, From AH, Zhang J: 
Xenotransplantation of long-term-cultured swine bone marrow-derived 
mesenchymal stem cells. Stem Cells 2007, 25:612-620.
77. Heeschen C: Profoundly reduced neovascularization capacity of bone 
marrow mononuclear cells derived from patients with chronic ischemic 
heart disease. Circulation 2004, 109:1615-1622.
78. Vasa M: Number and migratory activity of circulating endothelial 
progenitor cells inversely correlate with risk factors for coronary artery 
disease. Circ Res 2001, 89:E1-E7.
79. Hill J: Circulating endothelial progenitor cells, vascular function, and 
cardiovascular risk. N Eng J Med 2003, 348:593-600.
80. Edelberg J, Tang L, Hattori K, Lyden D, Rafi i S: Young adult bone marrow-
derived endothelial precursor cells restore aging-impaired cardiac 
angiogenic function. Circ Res 2002, 90:E89-E93.
81. Torella D: Cardiac stem cell and myocyte aging, heart failure, and insulin-
like growth factor-1 overexpression. Circ Res 2004, 94:514-524.
82. Assmus B: Hmg-coa reductase inhibitors reduce senescence and increase 
proliferation of endothelial progenitor cells via regulation of cell cycle 
regulatory genes. Circ Res 2003, 92:1049-1055.
83. Spyridopoulos I: Statins enhance migratory capacity by upregulation of 
the telomere repeat-binding factor trf2 in endothelial progenitor cells. 
Circulation 2004, 110:3136-3142.
84. Hong SJ, Choi SC, Kim JS, Shim WJ, Park SM, Ahn CM, Park JH, Kim YH, Lim DS: 
Low-dose versus moderate-dose atorvastatin after acute myocardial 
infarction: 8-month eff ects on coronary fl ow reserve and angiogenic cell 
mobilisation. Heart 2010, 96:756-764.
85. Smits AM, van VP, Hassink RJ, Goumans MJ, Doevendans PA: The role of stem 
cells in cardiac regeneration. J Cell Mol Med 2005, 9:25-36.
86. Davani S, Deschaseaux F, Chalmers D, Tiberghien P, Kantelip JP: Can stem 
cells mend a broken heart? Cardiovasc Res 2005, 65:305-316.
87. Planat-Benard V: Spontaneous cardiomyocyte diff erentiation from adipose 
tissue stroma cells. Circ Res 2004, 94:223-229.
88. Jiang Y: Multipotent progenitor cells can be isolated from postnatal 
murine bone marrow, muscle, and brain. Exp Hematol 2002, 30:896-904.
89. Jiang Y: Pluripotency of mesenchymal stem cells derived from adult 
marrow. Nature 2002, 418:41-49.
90. Kogler G: A new human somatic stem cell from placental cord blood with 
intrinsic pluripotent diff erentiation potential. J Exp Med 2004, 200:123-135.
91. Beltrami A: Adult cardiac stem cells are multipotent and support 
myocardial regeneration. Cell 2003, 114:763-776.
92. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S: 
Induction of pluripotent stem cells from adult human fi broblasts by 
defi ned factors. Cell 2007, 131:861-872.
93. Meluzin J, Mayer J, Groch L: Autologous transplantation of mononuclear 
bone marrow cells in patients with acute myocardial infarction: The eff ect 
of the dose of transplanted cells on myocardial function. Am Heart J 2006, 
152:e9-e15.
94. Fernández-Avilés F, San Román JA, García-Frade J, Fernández ME, Peñarrubia 
MJ, de la Fuente L, Gómez-Bueno M, Cantalapiedra A, Fernández J, Gutierrez 
O, Sánchez PL, Hernández C, Sanz R, García-Sancho J, Sánchez A: 
Experimental and clinical regenerative capability of human bone marrow 
cells after myocardial infarction. Circ Res 2004, 95:742-748.
95. De Lezo J, Herrera C, Pan M: Regenerative therapy in patients with a 
revascularized acute anterior myocardial infarction and depressed 
ventricular function. Rev Esp Cardiol 2007, 60:357-365.
96. Zhan-quan L, Ming Z: The clinical study of autologous peripheral blood 
stem cell transplantation by intracoronary infusion in patients with acute 
myocardial infarction. Int J Cardiol 2007, 115:52-56.
97. Lipiec P, Pakula M, Plewka M: Impact of intracoronary injection of 
mononuclear bone marrow cells in acute myocardial infarction on left 
ventricular perfusion and function: a 6-month follow-up gated mTc-MIBI 
single-photon emission computed tomography study. Eur J Nuclear Mol 
Imaging 2009, 36:587-593.
98. Huikuri H, Kervinen K, Niemelä M: Eff ects of intracoronary injection of 
mononuclear bone marrow cells on left ventricular function, arrhythmia 
risk profi le, and restonosis after thrombolytic therapy of acute myocardial 
infarction. Eur Heart J 2008, 29:2723-2732.
99. Kang H, Kim H, Zhang S, Park K, Cho H, Koo B: Eff ects of intracoronary 
infusion of peripheral blood stem-cells mobilised with granulocyte-
colony stimulating factor on left ventricular systolic function and 
restenosis after coronary stenting in myocardial infarction: the MAGIC cell 
randomised clinical trial. Lancet 2004, 363:751-756.
100. Bartunek J, Vanderheyden M, Vandekerckhove B: Intracoronary injection of 
CD133 positive enriched bone marrow progenitor cells promotes cardiac 
recovery after recent myocardial infarction: feasibility and safety. 
Circulation 2005, 112:I-178-I-183.
101. Chen SL, Fang WW, Ye F, Liu YH, Qian J, Shan SJ, Zhang JJ, Chunhua RZ, Liao 
LM, Lin S, Sun JP: Eff ect on left ventricular function of intracoronary 
transplantation of autologous bone marrow mesenchymal stem cell in 
patients with acute myocardial infarction. Am J Cardiol 2004, 94:92-95.
doi:10.1186/scrt93
Cite this article as: Arnous S, et al.: Bone marrow mononuclear cells and 
acute myocardial infarction. Stem Cell Research & Therapy 2012, 3:2.
Arnous et al. Stem Cell Research & Therapy 2012, 3:2 
http://stemcellres.com/content/3/1/2
Page 9 of 9
